The global colorectal cancer therapeutics market was valued at USD 11.5 billion in 2022 and is projected to reach USD 13.9 billion in 2026 and USD 16.7 billion by 2030, expanding at a CAGR of 4.7% from 2023 to 2030. Market growth is driven by the increasing prevalence of colorectal cancer, advancements in cancer screening and diagnostics, the introduction of targeted therapies, and growing adoption of immunotherapy.

North America dominated the global market in 2022, accounting for 42.6% of total revenue. The region's leadership is supported by established healthcare infrastructure, greater awareness of colorectal cancer, access to advanced treatment options, and the presence of major pharmaceutical companies. The U.S. represents a significant contributor to regional market revenue.

According to a study published in the National Library of Medicine in October 2021, colorectal cancer accounted for approximately 10.0% of global cancer cases and 9.4% of cancer-related deaths in 2020, making it the second-deadliest cancer worldwide after lung cancer, which accounted for 18.0% of cancer deaths.

Key Market Trends & Insights

• North America dominated the global market in 2022, accounting for 42.6% of total revenue, driven by advanced healthcare infrastructure, improved diagnostic capabilities, and the availability of innovative cancer treatments.
• The U.S. was the leading contributor to the North American colorectal cancer therapeutics market in 2022.
• Immunotherapy dominated the drug class segment, accounting for 83.0% of market revenue in 2022, reflecting the growing adoption of immune-based treatment approaches.
• Increasing colorectal cancer prevalence is creating demand for effective therapeutic solutions, particularly targeted treatments and advanced immunotherapies.
• Advancements in precision medicine and genomic profiling are supporting the development of personalized treatment strategies for patients with specific genetic alterations.
• Growing biosimilar adoption and patent expirations are creating opportunities for pharmaceutical manufacturers to expand treatment accessibility and market penetration.

Go Deeper! Ask Prism AI

about the Global organic personal care ingredients market. Get instant answers to questions related to market sizing, growth drivers & their impact, and more.

Colorectal Cancer Therapeutics Market Size & Forecast

Colorectal Cancer Therapeutics Market Growth Drivers

Increasing Prevalence of Colorectal Cancer

The rising global incidence of colorectal cancer is a major factor driving demand for effective therapeutic solutions. Although the exact causes of colorectal cancer remain unclear, several environmental, lifestyle-related, and genetic factors are associated with an increased risk of developing the disease.

According to the American Cancer Society's Colorectal Cancer Facts & Figures 2020–2022, approximately 1 in 25 women and 1 in 23 men in the U.S. are estimated to develop colorectal cancer during their lifetime.

Similarly, the World Health Organization reported that approximately 2 million people worldwide were diagnosed with colorectal cancer in 2020. The substantial disease burden is increasing the need for effective treatment options, including chemotherapy, targeted therapies, immunotherapy, and combination treatment approaches.

Download a free sample report or claim your copy of this full market intelligence report

Advancements in Screening, Diagnostics, and Treatment

Improvements in colorectal cancer screening, diagnostic technologies, and therapeutic approaches are supporting market expansion. Earlier disease detection and advances in treatment have contributed to declining colorectal cancer mortality rates in several populations.

The growing availability of precision medicine and molecular diagnostic technologies is also improving treatment selection by helping healthcare providers identify specific genetic alterations and biomarkers associated with colorectal cancer.

For instance, in June 2023, the U.S. Food and Drug Administration (FDA) approved the use of FoundationOne Liquid CDx genomic profiling to identify patients with BRAF V600E alterations in metastatic colorectal cancer. The test supports the identification of patients eligible for treatment with BRAFTOVI in combination with cetuximab, facilitating more targeted treatment decisions.

Growing Adoption of Targeted Therapies and Immunotherapy

The increasing acceptance of advanced cancer treatments is another important factor supporting market growth. Pharmaceutical companies are developing innovative therapies designed to target specific molecular pathways and improve treatment outcomes.

Therapies such as Avastin (bevacizumab), Erbitux (cetuximab), and Stivarga (regorafenib) have contributed to the evolution of colorectal cancer treatment.

Additionally, the development of biologics and immunotherapies, including Vectibix (panitumumab) and ZALTRAP (ziv-aflibercept), is expanding the available treatment landscape. Continued research into combination therapies and biomarker-driven treatment approaches is expected to create further opportunities for market participants.

Looking for more in-depth data focusing on specific segments or regions? Get this report customized with inclusion of custom data sets to suit your exact business needs.

Colorectal Cancer Therapeutics Market: Regional Insights

North America

North America dominated the global colorectal cancer therapeutics market in 2022, accounting for 42.6% of total revenue. The region's leadership is supported by advanced healthcare infrastructure, greater awareness of colorectal cancer, established reimbursement systems, and the availability of innovative cancer treatments.

The U.S. was the largest contributor to the regional market, supported by the presence of major pharmaceutical companies, increasing adoption of targeted therapies, and advancements in cancer diagnostics and treatment.

United States

The U.S. colorectal cancer therapeutics market plays a significant role in North America's overall market performance. Government initiatives, growing screening awareness, access to advanced treatment options, and the introduction of precision medicine technologies are supporting market development.

The increasing availability of genomic profiling and biomarker-based testing is also improving patient identification for targeted treatment approaches.

Explore the full list of profiled companies operating in this market with recent strategic initiatives

Key Companies & Market Share Insights

Companies operating in the global colorectal cancer therapeutics market are focusing on product approvals, new drug launches, strategic collaborations, mergers and acquisitions, and geographic expansion to strengthen their competitive positions.

Strategic partnerships are enabling pharmaceutical companies to expand their commercial reach, access innovative drug candidates, and strengthen their oncology portfolios.

For instance, in January 2023, Takeda Pharmaceutical Company entered into a partnership with Hong Kong-based Hutchmed to obtain commercial rights for the colorectal cancer drug fruquintinib outside China. The collaboration represents an effort to expand the geographic availability of innovative colorectal cancer treatments.

Additionally, Roche has been evaluating combinations of its targeted therapy Cotellic (cobimetinib) with immuno-oncology agents for colorectal cancer treatment. Such research initiatives highlight the industry's growing focus on combination therapies and new treatment approaches.

The major companies operating in the global colorectal cancer therapeutics market include:

• Amgen, Inc.
• Bayer AG
• Bristol Myers Squibb Company
• Eli Lilly and Company
• Merck & Co., Inc.
• F. Hoffmann-La Roche Ltd.
• Sanofi

Explore our dedicated business services:

U.S. Healthcare Facility Mapping & Intelligence Platform: Get facility-level intelligence to guide smarter decisions. Sign up Today